Biology subjects

Deng, I. B.

Publications and source records attributed to Deng, I. B..

4 recordsLinked to original sources

bioRxiv2026

Vps35 p.D620N causes Lrrk2 kinase hyperactivity, chronic microglial activation and inflammation

Pathogenic variants in leucine-rich repeat kinase 2 (LRRK2), RAB32, and vacuolar protein sorting 35 (VPS35) cause dominantly inherited, late-onset Parkinson's disease (PD). Mutations in all three genes constitutively activate LRRK2 kinase activity, enhancing innate immune defense against pathogens; however, chronic activation is linked to dopaminergic neuronal degeneration. LRRK2 and RAB32 are highly expressed in all myeloid cells including brain microglia, whereas VPS35, a core component of the retromer, is ubiquitously expressed. Nevertheless, the VPS35 p.D620N substitution induces the greatest constitutive increase in endogenous LRRK2 kinase activity, and its consequences for immune function remain unclear. We therefore examined the transcriptomic and functional effects of wild type (WT) and Vps35 p.D620N knock-in mice (VKI) from microglia, isolated from brains of naive animals at six-month of age, and initially analyzed by single-cell RNA sequencing (scRNAseq). Despite the absence of overt behavioral differences, differential gene expression revealed genotype-dependent changes in antimicrobial humoral immunity, lysosomal stress sensing, and phagocytosis. S100 family genes and lipocalin 2 were markedly upregulated, a finding subsequently validated by gene expression and immunohistochemistry. Downregulation was also observed in pathways governing microglial regulation of synaptic transmission, neuronal development and homeostatic immune signaling. Peripherally-administered lipopolysaccharide (LPS) stimulated microglial activation and phagocytic markers in WT brain, and further increased morphological activation and synaptic engulfment in VKI animals. Compared to WT, Vps35 p.D620N drives a chronic pro-inflammatory microglial state characterized by elevated innate immune signaling, lysosomal stress and enhanced phagocytic activity. Hence, heightened microglial sensitivity, further exacerbated by a peripheral immune challenge, offers a parsimonious, if multicellular, explanation for the multifactorial etiology of PD, and may help to account for its penetrance and variable expressivity. Together, these findings provide mechanistic insight into how retromer dysfunction and LRRK2 kinase hyperactivity intersect with microglial biology to influence PD pathogenesis, potentially promoting synaptic remodeling and neurodegenerative vulnerability.

neuroscience↗

bioRxiv2025

Peripheral inflammation mediates midbrain Lrrk2 kinase activity via Rab32 expression

Mutations that increase leucine-rich repeat kinase 2 (LRRK2) activity confer significant risk for Parkinsons disease (PD), yet incomplete disease penetrance suggest additional factors are required to manifest disease. We recently identified RAB32 Ser71Arg as a Mendelian gene for PD. Here, we establish Rab32 as a key mediator linking peripheral inflammation to Lrrk2 activation. We show that Rab32 and Rab38 expression are modestly, but inversely, correlated with their homolog Rab29. In vivo, peripheral lipopolysaccharide (LPS)-induced inflammation selectively induced Rab32 expression in midbrain Iba1+ microglia but not dopaminergic neurons, where it localized to Lamp1+ lysosomal compartments and correlated with Lrrk2 kinase activity. LPS similarly induces Rab32 expression in human induced pluripotent stem cell-derived microglia, demonstrating a unified biological response to inflammation across species. Promoter analysis identified Tfe3, a master regulator of lysosomal biogenesis and autophagy, as a key driver of Rab32 expression induced Lrrk2 kinase activation. During inflammation, Tfe3 translocated to the nucleus of midbrain Iba1+ microglia to induce Rab32 expression and Lrrk2 kinase activity. Knockdown of Tfe3, but not Tfeb, mitigates these effects, establishing Rab32 as a physiological rheostat of Lrrk2 activity. This mechanistic pathway enables peripheral inflammation to modulate LRRK2 activity and highlights Rab32/Tfe3 as a therapeutic targeting for neuroprotection in PD.

cell biology↗

bioRxiv2024

Characterization of Dnajc12 knockout mice, a model of hypodopaminergia

Homozygous DNAJC12 c.79-2A>G (p. V27Wfs*14) loss-of-function mutations were first reported as a cause of young-onset Parkinsons disease. However, bi-allelic autosomal recessive pathogenic variants in DNAJC12 may lead to an alternative constellation of neurological features, including infantile dystonia, developmental delay, intellectual disability and neuropsychiatric disorders. DNAJC12 is understood to co-chaperone aromatic amino acid hydroxylases to foster the synthesis of biogenic amines. In vitro, we discover overexpressed DNAJC12 forms a complex with guanine triphosphate cyclohydrolase 1 (GCH1), the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, a cofactor paramount for biogenic amines synthesis. We also confirm DNAJC12s interaction with tyrosine (TH) and tryptophan hydroxylase (TPH), which are rate-limiting enzymes for synthesis of biogenic amines dopamine (DA) and serotonin (5-HT). In-vitro knock-down of DNAJC12 with a siRNA destabilizes the DNAJC12-TH-GCH1 complex, reducing GCH1 levels, whereas reciprocal overexpression of both TH and GCH1 increases endogenous DNAJC12, alluding to the significance of modulating the DNAJC12-TH-GCH1 complex as a therapy for DNAJC12 and other biogenic amine disorders. We extend these investigations to a Cre-conditional knock-out mice (cDKO) in which loxP sites flanking Dnajc12 exon 2 enable its excision by cre-recombinase. With germline Cre expression, we have created a constitutive Dnajc12 knock-out (DKO). DKO mice exhibit reduced locomotion/ exploratory behavior at 3 months in automated open-field testing, accompanied by increased plasma phenylalanine which is a cardinal feature of patients with pathogenic DNAJC12 variants. In striatal tissue, total DA and 5-HT, their metabolites, and electrically-evoked DA release are all reduced. Biochemical alterations in synaptic proteins are also apparent, with enhanced phosphorylation of Th pSer31 and pSer40 reflecting biological compensation. Most immediately, cDKO and DKO mice present models to develop and refine therapeutic approaches for biogenic amines disorders, including dystonia and parkinsonism. They will also enable the pleiotropic functions of biogenic amines (including DA), usually synthesized in the brain or periphery, to be separated.

neuroscience↗

bioRxiv2023

Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine dynamics in VPS35 p.D620N knock-in mice

Dysregulation of dopamine neurotransmission profoundly affects motor, motivation and learning behaviors, and is often observed during the prodromal phase of Parkinsons disease (PD). However, the mechanism underlying these pathophysiological changes remains to be elucidated. Mutations in vacuolar protein sorting 35 (VPS35) and leucine-rich repeat kinase 2 (LRRK2) both lead to autosomal dominant PD, and VPS35 and LRRK2 may physically interact to govern the trafficking of synaptic cargos within the endo-lysosomal network in a kinase-dependent manner. To better understand the functional role of VPS35 and LRRK2 on dopamine physiology, we examined Vps35 haploinsufficient (Haplo) and Vps35 p.D620N knock-in (VKI) mice and how their behavior, dopamine kinetics and biochemistry are influenced by LRRK2 kinase inhibitors. We found Vps35 p.D620N significantly elevates LRRK2-mediated phosphorylation of Rab10, Rab12 and Rab29. In contrast, Vps35 haploinsufficiency reduces phosphorylation of Rab12. While striatal dopamine transporter (DAT) expression and function is similarly impaired in both VKI and Haplo mice, that physiology is normalized in VKI by treatment with the LRRK2 kinase inhibitor, MLi-2. As a corollary, VKI animals show a significant increase in amphetamine induced hyperlocomotion, compared to Haplo mice, that is also abolished by MLi-2. Taken together, these data show Vps35 p.D620N confers a gain-of-function with respect to LRRK2 kinase activation, and VPS35 and LRRK2 functionally interact to regulate DAT trafficking and striatal dopamine neurotransmission.

neuroscience↗